Takeda (TAK): 11.6x Core Earnings or 52.8x Reported? The 740 Billion Yen Gap

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2026 — Q1 FY2026 (three months ended June 30, 2026) revenue was JPY 1,219.9B, +10.2% at actual exchange rates but MINUS 0.5% at constant exchange rates. Core operating profit JPY 358.9B, +11.5% AER / -0.5% CER, at a 29.4% margin. Reported operating profit JPY 201.4B (+9.1%). Reported EPS JPY 71.65, DOWN 9.8% Y/Y. Core EPS JPY 154 (+1.5% AER, -11.8% CER). Adjusted free cash flow JPY 68.6B, down 63.9% from JPY 190.1B. FY2026 guidance reaffirmed in full: revenue JPY 4,640.0B, reported operating profit JPY 420.0B, core operating profit JPY 1,160.0B (guided DOWN 5-8% at CER), reported EPS JPY 104, core EPS JPY 472 (guided down mid-teens % at CER), adjusted FCF JPY 650-750B, dividend JPY 204/share. ADR NOTE: 1 Takeda ADS = 0.5 ordinary shares, so every yen-per-share figure HALVES per ADS; converted here at spot USD/JPY 159.46 on July 30, 2026. Do not use vendor per-share data for this ADR. Takeda reaffirmed everything and the ADR still fell ~3% — on a day the yen STRENGTHENED 2.4%, which is a tailwind for an ADR. Three things get missed. First, the entire +10.2% revenue growth is currency: at constant exchange rates revenue was -0.5% and core EPS -11.8%. Takeda's own sensitivity table (appendix A-15) says a 1% weaker yen adds JPY 20.6B of revenue but only JPY 0.42B of reported operating profit — and SUBTRACTS JPY 0.34B of net profit. That is why revenue rose 10% while reported EPS fell 9.8%. Second, the 'cheap' 11.6x core-earnings multiple excludes JPY 740B a year of charges Takeda forecasts itself: reported operating profit JPY 420.0B + JPY 413.5B product-intangible amortisation + JPY 100.0B budgeted impairments + JPY 226.5B other = JPY 1,160.0B core. That is 64% of core operating profit, and on reported earnings the ADR is at 52.8x. Third, the reaffirmed guide implies a violent second half: Q1's JPY 71.65 reported EPS is 69% of the JPY 104 full-year forecast, and the remaining three quarters imply just ~JPY 72.9B of reported operating profit each, a 64% step down from Q1. Also: adjusted net debt/adjusted EBITDA went UP from 2.6x to 2.7x against a 2.0x target, cash fell JPY 595.1B to JPY 461.0B, and Q1's JPY 150.1B dividend payment was ~6x that quarter's JPY 24.4B of pure free cash flow (though the dividend is covered ~2x across the full year). Our owner-earnings DCF with an explicit LOE-cliff assumption gives $7/ADS if the cliff bites and $23/ADS if the three launches deliver; at 55/45 that blends to about $16 versus $17.21 today. Our call: FAIRLY VALUED, 3/5, versus a Street Buy near $19-21. THE CALL: FAIRLY VALUED (3/5, NO MARGIN OF SAFETY AT $17 — THE PRICE ALREADY IMPLIES A 64% CHANCE THE THREE LAUNCHES REPLACE THE PATENT CLIFF) — base-case value ~$16.00 vs ~$17.21 today. What to watch: turns us bullish: two of the three launches (oveporexton/ORZEYFUL, rusfertide, zasocitinib) reaching real commercial scale with disclosed revenue, plus adjusted net debt/adjusted EBITDA back under 2.5x and adjusted free cash flow tracking to the JPY 650-750B guide rather than back-loading it. Breaks if USD/JPY heads back toward 170 (that alone cuts our fair value to about $14.70 on translation), if oveporexton slips in the US or Japan, if zasocitinib launches slowly into a heavily rebated psoriasis market, or if leverage pushes through 2.8x. Watch the December 11, 2026 Capital Markets Day. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.